Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

World TB Day 2015: new drugs, new methods, new guidance

This article was originally published in Scrip

Executive Summary

World TB Day, which takes place each year on 24 March, is the event at which bodies like the World Health Organization and the Stop TB Partnership report on progress with efforts to fight TB and exhort governments, civil society groups, healthcare providers and others to speed up those efforts.

You may also be interested in...



Pharma, Non-Profits Ally To Advance TB Drug Combinations

The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) is pulling together philanthropic, non-profit and private sector participants to collaboratively run Phase II trials for five drugs from Janssen, Otsuka, the TB Alliance and the Bill & Melinda Gates Medical Research Institute.

Changes To EU Pharma Reform: More Questions Than Answers?

In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.

Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages

The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC028200

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel